While there is currently no specific cure for Zellweger Spectrum Disorder (ZSD), researchers and clinicians are continuously exploring innovative therapeutic approaches to manage the condition and improve patient outcomes. A recent clinical report detailed the first use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a patient with PEX1-related ZSD, specifically the milder Infantile Refsum Disease (IRD) phenotype, opening a new avenue for potential treatment.
Zellweger Spectrum Disorder encompasses a continuum of disease severity, ranging from the severe Zellweger Syndrome, which is typically fatal in infancy, to milder forms like IRD. These disorders are characterized by defective peroxisome biogenesis, leading to the accumulation of very-long-chain fatty acids (VLCFAs) and profound neurological impairments, including leukodystrophy, hearing loss, and vision loss. The study focused on a three-year-old boy diagnosed with IRD after his older brother succumbed to a more severe form of the disease. Given the lack of effective treatments and the poor prognosis associated with the condition, the medical team, with parental consent, opted for allo-HSCT using an unrelated matched donor.
Stem cell transplantation has been used successfully to treat other metabolic disorders, such as X-linked adrenoleukodystrophy (X-ALD), by providing a source of cells with functional enzymes that can cross the blood-brain barrier and halt neurological decline. Applying this rationale to ZSD, the patient underwent a reduced-toxicity conditioning regimen, including busulfan, fludarabine, cyclophosphamide, and anti-thymocyte globulin, before receiving the stem cell transplant. The goal was to replace the patient's defective immune and hematopoietic system with healthy donor cells capable of normal peroxisomal function.
The short-term results of this intervention were remarkably positive. Following successful engraftment, the patient's plasma VLCFA levels, which are typically elevated in ZSD due to peroxisomal dysfunction, returned to normal reference values within 90 days post-transplantation. This biochemical normalization is a critical indicator that the donor cells were effectively metabolizing the toxic fatty acids. Furthermore, brain MRI scans showed improvement in the abnormal signal intensities previously observed in the paraventricular white matter, suggesting a stabilization or even reversal of the leukodystrophy.
Clinically, the patient recovered well without any severe transplant-related complications, such as graft-versus-host disease. During the two-year follow-up period, there was no deterioration in his hearing or cognitive function, and he continued to develop communication skills. This case suggests that allo-HSCT may offer a viable therapeutic option for a subgroup of ZSD patients, particularly those with milder phenotypes who are treated early in the disease course before irreversible neurological damage occurs. While long-term follow-up and larger clinical trials are necessary to fully determine the efficacy and safety of this approach, the initial findings provide a glimmer of hope for families affected by this devastating disorder.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.